Copyright
©The Author(s) 2019.
World J Gastroenterol. Feb 14, 2019; 25(6): 659-671
Published online Feb 14, 2019. doi: 10.3748/wjg.v25.i6.659
Published online Feb 14, 2019. doi: 10.3748/wjg.v25.i6.659
Figure 1 Lifetime incidence of various cancers associated with primary sclerosing cholangitis and their respective risks compared with the general population.
Estimations of lifetime incidence are made from limited available data (predominantly based on 10- to 30-year longitudinal studies), and thus may often underestimate true lifetime risk. 1The risk in patients with PSC-IBD (not PSC alone) is 4× the risk in patients with UC alone and 10× the risk in the general population. PSC: Primary sclerosing cholangitis; PSC-IBD: Inflammatory bowel disease co-existing with primary sclerosing cholangitis; UC: Ulcerative colitis.
- Citation: Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol 2019; 25(6): 659-671
- URL: https://www.wjgnet.com/1007-9327/full/v25/i6/659.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i6.659